Neurogene (NGNE) Research & Development (2013 - 2026)
Neurogene (NGNE) posted Research & Development of $25.2 million for Q1 2026, up 21.86% on a QoQ basis from $20.6 million in Q4 2025, and up 41.61% year-over-year from $17.8 million in Q1 2025.
Neurogene (NGNE) Research & Development (2013 - 2026) Analysis & Trends
Neurogene's Research & Development history runs 14 years deep, the most recent figure standing at $25.2 million for Q1 2026.
- Quarterly Research & Development rose 41.61% year-over-year to $25.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $82.4 million (up 26.5% YoY) and the FY2025 annual result came in at $75.0 million, up 23.14% from the prior year.
- Research & Development was $25.2 million for Q1 2026 at Neurogene, up from $20.6 million in the prior quarter.
- Across five years, Research & Development topped out at $25.2 million in Q1 2026 and bottomed at $9.5 million in Q3 2022.
- A 5-year average of $14.9 million and a median of $15.3 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development jumped 67.8% — and 2023, when it retreated 25.6%.
- Neurogene's Research & Development stood at $16.4 million in 2022, then fell by 25.6% to $12.2 million in 2023, then rose by 25.96% to $15.3 million in 2024, then soared by 34.48% to $20.6 million in 2025, then gained by 21.86% to $25.2 million in 2026.
- Business Quant data shows NGNE's Research & Development at $25.2 million in Q1 2026, $20.6 million in Q4 2025, and $17.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Neurogene | 776.69 Mn | 776.69 Mn | - | 25.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.15 Mn |
| Dec 31, 2025 | 20.64 Mn |
| Sep 30, 2025 | 17.24 Mn |
| Jun 30, 2025 | 19.37 Mn |
| Mar 31, 2025 | 17.76 Mn |
| Dec 31, 2024 | 15.35 Mn |
| Sep 30, 2024 | 16.29 Mn |
| Jun 30, 2024 | 15.74 Mn |
| Mar 31, 2024 | 13.54 Mn |
| Dec 31, 2023 | 12.18 Mn |
| Sep 30, 2023 | 11.61 Mn |
| Jun 30, 2023 | 10.32 Mn |
| Mar 31, 2023 | 10.28 Mn |
| Dec 31, 2022 | 16.38 Mn |
| Sep 30, 2022 | 9.47 Mn |
| Jun 30, 2022 | 10.96 Mn |
| Mar 31, 2022 | 10.70 Mn |
| Dec 31, 2021 | 9.76 Mn |
| Sep 30, 2021 | 9.90 Mn |
| Jun 30, 2021 | 9.82 Mn |